Editor’s note: The archived video recording is embedded below.
The need to respond to the coronavirus pandemic is forcing technology-enabled change in health care at an unprecedented speed. Barriers that have existed for years — whether regulatory, logistical, or scientific — are falling. Join STAT for a four-part digital event series jointly developed and delivered by Harvard Medical School to discuss everything from the rapid deployment of telehealth to the development of drugs and vaccines. The first part took place on May 7 and discussed new biopharma collaborative models for Covid-19.
This series will take place on Zoom, and attendees will be able to both see the discussions live and participate by asking questions. Access to the event is free. Access to the Zoom platform is limited to the first 1,000 attendees; any additional attendees will be able to watch the conversation in real time via a livestream below.
Part 2: Telemedicine during the Covid-19 pandemic — the new normal? May 12 at 1 p.m. ET
- John Glaser Ph.D., president, American Telemedicine Association; former, senior vice president, population health, Cerner; former CEO, Siemens Health Services
- Lee Schwamm, M.D., vice president of virtual care, Partners Healthcare Digital Health; director, MGH Center for TeleHealth; executive vice chairman, Department of Neurology, Massachusetts General Hospital
- Erin Brodwin, health tech correspondent, San Francisco, STAT
- Stanley Y. Shaw, M.D., Ph.D., associate dean for executive education, Harvard Medical School